<DOC>
	<DOCNO>NCT00329849</DOCNO>
	<brief_summary>Safety immunogenicity meningococcal ACWY conjugate versus polysaccharide vaccine child 2 10 year age</brief_summary>
	<brief_title>Safety Immunogenicity Meningococcal ACWY Conjugate Versus Polysaccharide Vaccine Children 2 10 Years Age</brief_title>
	<detailed_description />
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy child 2 10 year age inclusive whose parent legal guardian give write informed consent time enrollment ; Available visit telephone call ( parent legal guardian ) schedule study ; Good health determine clinical judgment investigator . Individuals eligible enrol study : whose parent legal guardian unwilling unable give write informed consent participate study ; whose parent legal guardian perceive unreliable unavailable duration study period ; previous suspect disease cause N meningitidis ; household contact and/or intimate exposure individual cultureproven N. meningitidis infection within 60 day prior enrollment ; previously immunize meningococcal vaccine vaccine contain meningococcal antigen ( ) ( licensed investigational ) ; receive investigational agent vaccine within 90 day prior enrollment expect receive investigational agent vaccine prior completion study ; receive licensed vaccine within one month prior enrollment receipt license vaccine anticipate within one month vaccination ( Exception : influenza vaccine could administer 15 day prior study vaccination le 15 day study vaccination ) ; receive live viral vaccine within 60 day prior enrollment ; experience , within 7 day prior enrollment , significant acute chronic infection ( example require systemic antibiotic treatment antiviral therapy ) experience fever ( defined axillary temperature ≥38°C ) within 3 day prior enrollment ; serious acute , chronic progressive disease ( e.g. , history neoplasm , cancer , diabetes , cardiac disease , autoimmune disease , Human Immunodeficiency Virus ( HIV ) infection Acquired Immune Deficiency Syndrome ( AIDS ) , blood dyscrasia , sign cardiac renal failure severe malnutrition ) . ( Exception : subject mild asthma eligible enrollment ; subject moderate severe asthma require routine use inhale systemic corticosteroid eligible enrollment ) ; epilepsy progressive neurological disease ; history anaphylaxis , serious vaccine reaction , allergy vaccine component ; know suspected impairment/alteration immune function , either congenital acquire result ( example ) : receipt immunosuppressive therapy within 30 day prior enrollment ( systemic corticosteroid administer 5 day , daily dose &gt; 1 mg/kg/day prednisone equivalent 30 day prior enrollment , cancer chemotherapy ) ; receipt immunostimulants ; receipt parenteral immunoglobulin preparation , blood product , and/or plasma derivative within 90 day prior enrollment full length study ; common childhood exanthematous disease ( varicella , mumps , measles , rubella ) occur 6 week prior vaccination ; know bleed diathesis condition could associate prolonged bleeding time ; Down syndrome know cytogenic disorder ; whose family plan leave area study site end study period ; condition , opinion investigator , could interfere evaluation study objective .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>10 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Meningitis</keyword>
	<keyword>child</keyword>
	<keyword>vaccine</keyword>
	<keyword>safety</keyword>
	<keyword>efficacy</keyword>
</DOC>